Evolution of screening for prostate cancer

Early diagnostic algorithms for prostate cancer has been dramatically changed for the last 20 years: from massive screening to individual risk-adapted strategy for well-informed patients in high risk group with estimated life expectancy 10–15 years. Utilization of modern PSA isoforms, new biological markers and mpMRI help to avoid unnecessary biopsies, overdiagnosis of clinically insignificant PCa and adverse outcomes of unreasonable treatment.